Status of adjuvant endocrine therapy for breast cancer

Breast Cancer Research

Volumn 16, Issue 2, 2014, Pages

  Schiavon, Gaia ^a,b   Smith, Ian E ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; EXEMESTANE; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; PLACEBO; TAMOXIFEN CITRATE; ZOLEDRONIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BODY FAT; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; COGNITION; DRUG EFFICACY; ENDOMETRIUM CANCER; FOLLOW UP; GENOTYPE; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; OVARIECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER REGRESSION; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG METABOLISM; DRUG SAFETY; HAZARD RATIO; LONG TERM CARE; LUNG EMBOLISM; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RISK FACTOR; BREAST NEOPLASMS; FEMALE; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84901997336     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3636     Document Type: Review

References (115)

1. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
2. Nunn T. On Cancer of the Breast 1882, London, UK: J. & A. Churchill.
3. Love RR, Philips J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 2002, 94:1433-1434. 10.1093/jnci/94.19.1433, 12359852.
4. Early Breast Cancer Trialists' Collaborative Group Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996, 348:1189-1196. Early Breast Cancer Trialists' Collaborative Group.
5. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467. Early Breast Cancer Trialists' Collaborative Group.
6. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352:930-942. Early Breast Cancer Trialists' Collaborative Group.
7. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by nolvadex adjuvant trial organisation. Lancet 1983, 1:257-261.
8. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant trial organisation. Br J Cancer 1988, 57:608-611. 2246455, 2900647.
9. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC adjuvant breast trial working party. Br J Cancer 1988, 57:604-607. 2246453, 2900646.
10. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL, Ketner M. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320:479-484. 10.1056/NEJM198902233200802, 2644532.
11. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from national surgical adjuvant breast and bowel project randomised clinical trials. Lancet 2004, 364:858-868. 10.1016/S0140-6736(04)16981-X, 15351193.
12. Early Breast Cancer Trialists' Collaborative Group Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988, 319:1681-1692. Early Breast Cancer Trialists' Collaborative Group.
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
14. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R, Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. 3163848, 21802721, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
15. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
16. Jordan VC. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 1995, 35:195-211. 10.1146/annurev.pa.35.040195.001211, 7598491.
17. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004, 85:151-159. 10.1023/B:BREA.0000025406.31193.e8, 15111773.
18. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764. 10.1093/jnci/djg108, 14652237.
19. Pharoah PD, Abraham J, Caldas C. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012, 104:1263-1264. author reply 1266-1268, 10.1093/jnci/djs312, 22851268.
20. Stanton V. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012, 104:1265-1266. author reply 1266-1268, 10.1093/jnci/djs305, 22851267.
21. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G, Breast International Group (BIG) 1-98 Collaborative Group CYP2D6 Genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012, 104:441-451. 10.1093/jnci/djs125, 3309132, 22395644, Breast International Group (BIG) 1-98 Collaborative Group.
22. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012, 104:452-460. 10.1093/jnci/djs126, 3611934, 22395643.
23. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 2012, 104:1264. author reply 1266-1268, 10.1093/jnci/djs304, 22851270.
24. Kelly CM, Pritchard KI. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Natl Cancer Inst 2012, 104:427-428. 10.1093/jnci/djs139, 22395645.
25. Rae JM, Regan M, Leyland-Jones B, Hayes DF, Dowsett M. CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer. J Clin Oncol 2013, 31:2753-2755.
26. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-1723.
27. Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005, 23:5973-5982. 10.1200/JCO.2005.05.551, 16087950.
28. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, Marth C, ABCSG-12 Trial Investigators Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691. 10.1056/NEJMoa0806285, 19213681, ABCSG-12 Trial Investigators.
29. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12:631-641. 10.1016/S1470-2045(11)70122-X, 21641868, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
30. Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011, 29:2653-2659. 10.1200/JCO.2010.33.2585, 21555684.
31. Hackshaw A, Baum M, Fornander T, Nordenskjold B, Nicolucci A, Monson K, Forsyth S, Reczko K, Johansson U, Fohlin H, Valentini M, Sainsbury R. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009, 101:341-349. 10.1093/jnci/djn498, 2650713, 19244174.
32. Dowsett M, Howell A. Breast cancer: aromatase inhibitors take on tamoxifen. Nat Med 2002, 8:1341-1344. 10.1038/nm1202-1341, 12457166.
33. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348:2431-2442. 10.1056/NEJMra023246, 12802030.
34. Lipton A, Santen RJ. Proceedings: medical adrenalectomy using Aminoglutethimide and Dexamethasone in advanced breast cancer. Cancer 1974, 33:503-512. 10.1002/1097-0142(197402)33:2<503::AID-CNCR2820330227>3.0.CO;2-L, 4812767.
35. Smith IE, Fitzharris BM, McKinna JA, Fahmy DR, Nash AG, Neville AM, Gazet JC, Ford HT, Powles TJ. Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet 1978, 2:646-649.
36. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 1981, 305:545-551. 10.1056/NEJM198109033051003, 7019703.
37. Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, Smith IE, McKinna JA, Nash A, Ford HT, Gazet JC. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol 1992, 10:1547-1552.
38. Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 2003, 21:984-990. 10.1200/JCO.2003.01.138, 12637461.
39. Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist 2008, 13:829-837. 10.1634/theoncologist.2008-0055, 18695261.
40. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, Dowsett M. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998, 4:2089-2093.
41. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002, 20:751-757. 10.1200/JCO.20.3.751, 11821457.
42. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
43. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A, Breast International Group (BIG) 1-98 Collaborative Group A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757. Breast International Group (BIG) 1-98 Collaborative Group.
44. Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel J, Paridaens R, Markopolous C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett JM, van de Velde CJ. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer [abstract 15]. Cancer Res 2009, 69:67s.
45. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, Intergroup Exemestane Study A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092. 10.1056/NEJMoa040331, 15014181, Intergroup Exemestane Study.
46. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 2012, 30:709-717. 10.1200/JCO.2010.33.7899, 22042946.
47. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007, 25:2664-2670. 10.1200/JCO.2006.08.8054, 17563395.
48. Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian breast and colorectal cancer study group. J Clin Oncol 2012, 30:722-728. 10.1200/JCO.2011.36.8993, 22271481.
49. Boccardo F, Guglielmini P, Bordonaro R, Fini A, Massidda B, Porpiglia M, Roagna R, Serra P, Orzalesi L, Ucci G, Rubagotti A. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian tamoxifen anastrozole trial. Eur J Cancer 2013, 49:1546-1554. 10.1016/j.ejca.2012.12.025, 23415888.
50. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802. 10.1056/NEJMoa032312, 14551341.
51. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H, Austrian Breast and Colorectal Cancer Study Group Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast and colorectal cancer study group trial 6a. J Natl Cancer Inst 2007, 99:1845-1853. 10.1093/jnci/djm246, 18073378, Austrian Breast and Colorectal Cancer Study Group.
52. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 2008, 26:1965-1971. 10.1200/JCO.2007.14.0228, 18332472.
53. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141. 10.1016/S1470-2045(10)70257-6, 21087898.
54. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B, BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 year median follow-up. Lancet Oncol 2011, 12:1101-1108. 10.1016/S1470-2045(11)70270-4, 3235950, 22018631, BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).
55. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011, 377:321-331. 10.1016/S0140-6736(10)62312-4, 21247627.
56. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012, 30:718-721. 10.1200/JCO.2010.34.4010, 3295549, 22042967.
57. Shao J, Chang M, Chow SC. Statistical inference for cancer trials with treatment switching. Stat Med 2005, 24:1783-1790. 10.1002/sim.2128, 15900586.
58. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000, 56:779-788. 10.1111/j.0006-341X.2000.00779.x, 10985216.
59. Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011, 29:1117-1124. 10.1200/JCO.2010.31.6455, 3083867, 21321298.
60. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
61. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492. 10.1200/JCO.2006.08.8617, 17200148.
62. Buzdar AU, on behalf of the ATAC Trialists' Group Clinical features of joint symptoms observed in the arimidex, tamoxifen, alone or in combination (ATAC) trial [abstract 551]. Proc Am Soc Clin Oncol 2006, 24:551. on behalf of the ATAC Trialists' Group.
63. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271. 10.1093/jnci/dji250, 16145047.
64. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS, BIG 1-98 Collaborative Group Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776. 2921823, 19692688, BIG 1-98 Collaborative Group.
65. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008, 26:1051-1057. 10.1200/JCO.2007.11.0726, 18309940.
66. Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F, Hasenburg A. Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol 2009, 20:1203-1209. 10.1093/annonc/mdn762, 19218306.
67. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635. 10.1200/JCO.2005.05.4882, 16822845.
68. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53.
69. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006, 7:633-643.
70. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 2007, 369:559-570. 10.1016/S0140-6736(07)60200-1, 17307102.
71. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 2011, 126:295-310. 10.1007/s10549-011-1351-3, 21249443.
72. Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 2012, 13:275-284. 10.1016/S1470-2045(11)70389-8, 22318095.
73. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw 2009, 7:S1-S32. quiz S33-S35, 3047391, 19878635.
74. Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416. 10.1093/annonc/mdn164, 18448451.
75. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S, American Society of Clinical Oncology American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057. 10.1200/JCO.2003.08.017, 12963702, American Society of Clinical Oncology.
76. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007, 9:R52. 10.1186/bcr1757, 2206728, 17692126.
77. McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007, 43:2523-2531. 10.1016/j.ejca.2007.08.029, 18029171.
78. Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006, 42:2968-2975. 10.1016/j.ejca.2006.07.005, 16963261.
79. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn S, Patel A, Coombes RC, Bliss JM, Kilburn LS, on behalf of the Intergroup Exemestane Study Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study (IES). 2008, 1128. San Antonio, TX: Paper presented at: 31st Annual San Antonio Breast Cancer Symposium, on behalf of the Intergroup Exemestane Study.
80. Cuzick J, Sestak I, Cella D, Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9:1143-1148. 10.1016/S1470-2045(08)70259-6, 18976959.
81. Pritchard KI. Endocrine symptoms to predict risk of recurrence?. Lancet Oncol 2008, 9:1117-1119. 10.1016/S1470-2045(08)70291-2, 19038757.
82. Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 2013, 31:2257-2264. 10.1200/JCO.2012.45.3068, 23610112.
83. Huober J, Cole BF, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, Bonnefoi H, Forbes JF, Neven P, Láng I, Smith I, Wardley A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Gelber RD, Thürlimann B, BIG 1-98 Collaborative and International Breast Cancer Study Groups Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 2014, 143:159-169. 10.1007/s10549-013-2792-7, 24305979, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
84. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 2009, 18:134-143. 10.1002/pon.1379, 18551510.
85. Side effects revisited: women's experiences with aromatase inhibitors. A report from breast cancer action. http://bcation.org/uploads/PDF/AIReport.pdf.
86. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? a pilot study. Psychooncology 2004, 13:61-66. 10.1002/pon.709, 14745746.
87. Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007, 14:995-998. 10.1097/gme.0b013e318148b28b, 2831410, 17898668.
88. Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010, 19:388-395. 10.1016/j.breast.2010.03.025, 2921449, 20385495.
89. Phillips KA, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2011, 126:221-226. 10.1007/s10549-010-1235-y, 3044608, 21046229.
90. Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009, 48:76-85. 10.1080/02841860802314738, 18777410.
91. Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010, 28:1294-1300. 10.1200/JCO.2008.21.3553, 20142601.
92. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A, Breast International Group Trial 1-98 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008, 26:5569-5575. 10.1200/JCO.2008.17.0829, 2651094, 18981464, Breast International Group Trial 1-98.
93. Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS, BIG 1-98 Collaborative and International Breast Cancer Study Groups Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011, 22:2201-2207. 10.1093/annonc/mdq738, 3179413, 21335417, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
94. Metzger O, Giobbie-Hurder A, Mallon E, Viale G, Winer E, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Bonnefoi H, Coates AS, Goldhirsch A, Gusterson B, BIG 1-98 Collaborative Group, and International Breast Cancer Study Group Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial [abstract]. Cancer Res 2012, 72:S1-1. BIG 1-98 Collaborative Group, and International Breast Cancer Study Group.
95. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19:3808-3816.
96. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005, 23:5108-5116. 10.1200/JCO.2005.04.005, 15998903.
97. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006, 24:3019-3025. 10.1200/JCO.2005.04.3034, 16754938.
98. Bartlett JM, Brookes CL, Piper T, van de Velde CJ, Stocken D, Lyttle N, Hasenburg A, Quintayo MA, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix LY, Seynaeve C, Rea DW. Do type 1 receptor tyrosine kinases inform treatment choice? a prospectively planned analysis of the TEAM trial. Br J Cancer 2013, 109:2453-2461. 10.1038/bjc.2013.609, 24091623.
99. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008, 26:1059-1065. 10.1200/JCO.2007.12.9437, 18227529.
100. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008, 9:23-28. 10.1016/S1470-2045(07)70386-8, 18083065, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
101. Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, Gelmon KA. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 2007, 18:45-51. 10.1093/annonc/mdl450, 17030545.
102. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008, 19:877-882. 10.1093/annonc/mdm566, 18332043.
103. Goss PE, Ingle JN, Martino S, Robert N, Muss H, Shepherd L, Pritchard KI, Livingston RB, Davidson N, Perez EA, Cameron D, Whelan T, Palmer M, Tu D. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial [abstract]. Cancer Res 2009, 69:487s.
104. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006, 99:295-300. 10.1007/s10549-006-9207-y, 16541302.
105. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008, 26:1948-1955. 10.1200/JCO.2007.11.6798, 18332475.
106. Markopoulos C, Dafni U, Misitzis J, Zobolas V, Tzoracoleftherakis E, Koukouras D, Xepapadakis G, Papadiamantis J, Venizelos B, Antonopoulou Z, Gogas H. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res 2009, 11:R35. 10.1186/bcr2320, 2716503, 19531217.
107. Goss PE, Mamounas EP, Jakesz R, Markopoulos C, Dowsett M, Peto R, Godwin J, Davies C. Aromatase inhibitors (AIs) versus not (placebo/observation) as late extended adjuvant therapy for postmenopausal women with early stage breast cancer: overviews of randomized trials of AIs after ~ 5 years of tamoxifen [abstract]. Cancer Res 2009, 69:733s.
108. Higgins MJ, Liedke PE, Goss PE. Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. Crit Rev Oncol Hematol 2013, 86:23-32. 10.1016/j.critrevonc.2012.09.013, 23116626.
109. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996, 88:1529-1542. 10.1093/jnci/88.21.1529, 8901851.
110. Tormey DC, Gray DC, Falkson HC, Eastern Cooperative Oncology Group Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996, 88:1828-1833. 10.1093/jnci/88.24.1828, 8961972, Eastern Cooperative Oncology Group.
111. Stewart HJ, Everington D, McDonald CC, Dewar JA, Hawkins RA, Prescott RJ, George WD, The Scottish Cancer Trials Breast Group Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer 1996, 74:297-299. 10.1038/bjc.1996.356, 2074573, 8688340, The Scottish Cancer Trials Breast Group.
112. Earl H, Gray R, Kerr D, Lee M. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom. Clin Oncol (R Coll Radiol) 1997, 9:141-143.
113. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381:805-816. 10.1016/S0140-6736(12)61963-1, 3596060, 23219286.
114. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T, Chetiyawardana S, Dewar JA, Fernando IN, Frieve R, Nicoll J, Rayter Z, Robinson A, Salman A, Yarnold J, Bathers S, Marshall A, Lee M, On behalf of the aTTom Collaborative Group aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 in 6,953 women with early breast cancer. 2013, Chicago, IL: Paper presented at: 49th Annual Meeting of the American Society of Clinical Oncology, Abstract 5, On behalf of the aTTom Collaborative Group.
115. Bianchini G, Gianni L. An unmet need: tailoring extended adjuvant endocrine therapy. Br J Cancer 2013, 109:2951-2953. 10.1038/bjc.2013.707, 3859956, 24253504.